Drug intelligence / Profile preview

Buzhong Tiaogan Granules

Development stage: Preclinical
Lead developer: Shanxi Provincial Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Buzhong Tiaogan Granules is a Traditional Chinese Medicine (TCM) formulation developed by the Shanxi Province Hospital of Traditional Chinese Medicine. It is currently being evaluated in clinical trials as a combination therapy alongside standard-of-care chemotherapy regimens—including CAPEOX, mFOLFOX6, or FOLFIRI, supplemented with bevacizumab or cetuximab—for patients with unresectable colorectal cancer and liver-dominant metastases. The treatment aims to improve clinical outcomes and safety profiles in the management of advanced colorectal cancer by integrating traditional herbal medicine with conventional oncology treatments.

Brand names: Buzhong Tiaogan Granules
Other names: Buzhong Tiaogan Granules

Beyond the preview

Go deeper on Buzhong Tiaogan Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Buzhong Tiaogan Granules.

Explore the full profile